Skip to main content
. 2022 Jan 27;6(3):e10304. doi: 10.1002/lrh2.10304

FIGURE 3.

FIGURE 3

Plot of weekly prevalence (%) of in‐hospital use of tocilizumab among patients who received high‐flow nasal cannula (HFNC), BiPAP/CPAP (NIV), or mechanical ventilation (MV). On the x‐axis, negative numbers reflect weeks prior to seminal event “A,” the date (January 9, 2021) in which tocilizumab trial results were published among critically ill patients with coronavirus disease 2019 (COVID‐19) who were receiving organ support